These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 38132831)

  • 1. Pan-cancer analysis of TIM-3 transcriptomic expression reveals high levels in pancreatic cancer and interpatient heterogeneity.
    Lim J; Kurzrock R; Nishizaki D; Miyashita H; Adashek JJ; Lee S; Pabla S; Nesline M; Conroy JM; DePietro P; Lippman SM; Kato S
    Cancer Med; 2024 Jan; 13(1):e6844. PubMed ID: 38132831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA methylation and repressive H3K9 and H3K27 trimethylation in the promoter regions of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, and PD-L1 genes in human primary breast cancer.
    Sasidharan Nair V; El Salhat H; Taha RZ; John A; Ali BR; Elkord E
    Clin Epigenetics; 2018; 10():78. PubMed ID: 29983831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune Co-inhibitory Receptors PD-1, CTLA-4, TIM-3, LAG-3, and TIGIT in Medullary Thyroid Cancers: A Large Cohort Study.
    Shi X; Li CW; Tan LC; Wen SS; Liao T; Zhang Y; Chen TZ; Ma B; Yu PC; Lu ZW; Qu N; Wang Y; Shi RL; Wang YL; Ji QH; Wei WJ
    J Clin Endocrinol Metab; 2021 Jan; 106(1):120-132. PubMed ID: 33000173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TIM-3 Dictates Functional Orientation of the Immune Infiltrate in Ovarian Cancer.
    Fucikova J; Rakova J; Hensler M; Kasikova L; Belicova L; Hladikova K; Truxova I; Skapa P; Laco J; Pecen L; Praznovec I; Halaska MJ; Brtnicky T; Kodet R; Fialova A; Pineau J; Gey A; Tartour E; Ryska A; Galluzzi L; Spisek R
    Clin Cancer Res; 2019 Aug; 25(15):4820-4831. PubMed ID: 31076549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Altered expression of TIM-3, LAG-3, IDO, PD-L1, and CTLA-4 during nimotuzumab therapy correlates with responses and prognosis of oral squamous cell carcinoma patients.
    Wang H; Mao L; Zhang T; Zhang L; Wu Y; Guo W; Hu J; Ju H; Ren G
    J Oral Pathol Med; 2019 Sep; 48(8):669-676. PubMed ID: 31132187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNA methylation and repressive histones in the promoters of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, PD-L1, and galectin-9 genes in human colorectal cancer.
    Sasidharan Nair V; Toor SM; Taha RZ; Shaath H; Elkord E
    Clin Epigenetics; 2018 Aug; 10(1):104. PubMed ID: 30081950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blockade of PD-1, PD-L1, and TIM-3 Altered Distinct Immune- and Cancer-Related Signaling Pathways in the Transcriptome of Human Breast Cancer Explants.
    Saleh R; Toor SM; Al-Ali D; Sasidharan Nair V; Elkord E
    Genes (Basel); 2020 Jun; 11(6):. PubMed ID: 32616706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of the expression of the immune checkpoint molecules PD-1, CTLA4, TIM-3 and LAG-3 across different cancers in relation to treatment response, tumor-infiltrating immune cells and survival.
    Tu L; Guan R; Yang H; Zhou Y; Hong W; Ma L; Zhao G; Yu M
    Int J Cancer; 2020 Jul; 147(2):423-439. PubMed ID: 31721169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Significance of immune checkpoint proteins in EGFR-mutant non-small cell lung cancer.
    Soo RA; Kim HR; Asuncion BR; Fazreen Z; Omar MFM; Herrera MC; Yun Lim JS; Sia G; Soong R; Cho BC
    Lung Cancer; 2017 Mar; 105():17-22. PubMed ID: 28236980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CTLA4 , PD-1 , PD-L1 , PD-L2 , TIM-3 , TIGIT , and LAG3 DNA Methylation Is Associated With BAP1 -Aberrancy, Transcriptional Activity, and Overall Survival in Uveal Melanoma.
    de Vos L; Carrillo Cano TM; Zarbl R; Klümper N; Ralser DJ; Franzen A; Herr E; Gabrielpillai J; Vogt TJ; Dietrich J; Strieth S; Landsberg J; Dietrich D
    J Immunother; 2022 Sep; 45(7):324-334. PubMed ID: 35862127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor-Infiltrating T Cells Concurrently Overexpress CD200R with Immune Checkpoints PD-1, CTLA-4, and TIM-3 in Non-Small-Cell Lung Cancer.
    Su Y; Yamazaki S; Morisue R; Suzuki J; Yoshikawa T; Nakatsura T; Tsuboi M; Ochiai A; Ishii G
    Pathobiology; 2021; 88(3):218-227. PubMed ID: 33321503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistochemical Expression of Immune Checkpoints; CTLA-4, LAG3, and TIM-3 in Cancer Cells and Tumor-infiltrating Lymphocytes (TILs) in Colorectal Carcinoma.
    Abdelrahman DI; Elhasadi I; Anbaig A; Bakry A; Mandour D; Wasefy T; Yehia AM; Alorini M; Shalaby AM; Yahia AIO; Alabiad MA
    Appl Immunohistochem Mol Morphol; 2024 Feb; 32(2):71-83. PubMed ID: 38108390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Viewing the immune checkpoint VISTA: landscape and outcomes across cancers.
    Nishizaki D; Kurzrock R; Miyashita H; Adashek JJ; Lee S; Nikanjam M; Eskander RN; Patel H; Botta GP; Nesline MK; Pabla S; Conroy JM; DePietro P; Sicklick JK; Kato S
    ESMO Open; 2024 Apr; 9(4):102942. PubMed ID: 38503143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence and prognostic significance of PD-L1, TIM-3 and B7-H3 expression in endometrial serous carcinoma.
    Chen H; Molberg K; Carrick K; Niu S; Rivera Colon G; Gwin K; Lewis C; Zheng W; Castrillon DH; Lucas E
    Mod Pathol; 2022 Dec; 35(12):1955-1965. PubMed ID: 35804040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Looking past PD-L1: expression of immune checkpoint TIM-3 and its ligand galectin-9 in cervical and vulvar squamous neoplasia.
    Curley J; Conaway MR; Chinn Z; Duska L; Stoler M; Mills AM
    Mod Pathol; 2020 Jun; 33(6):1182-1192. PubMed ID: 32139873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of PD-L1 and other immunotherapeutic targets in thymic epithelial tumors.
    Arbour KC; Naidoo J; Steele KE; Ni A; Moreira AL; Rekhtman N; Robbins PB; Karakunnel J; Rimner A; Huang J; Riely GJ; Hellmann MD
    PLoS One; 2017; 12(8):e0182665. PubMed ID: 28771603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TIM-3 transcriptomic landscape with clinical and immunomic correlates in cancer.
    Ahmed J; Nishizaki D; Miyashita H; Lee S; Nesline MK; Pabla S; Conroy JM; DePietro P; Sicklick JK; Kato S; Kurzrock R
    Am J Cancer Res; 2024; 14(5):2493-2506. PubMed ID: 38859842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of the Immune Checkpoint Regulators LAG-3 and TIM-3 in Classical Hodgkin Lymphoma.
    El Halabi L; Adam J; Gravelle P; Marty V; Danu A; Lazarovici J; Ribrag V; Bosq J; Camara-Clayette V; Laurent C; Ghez D
    Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):257-266.e3. PubMed ID: 33277223
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of B7-H3 and TIM-3 in gastric-type endocervical adenocarcinoma: prevalence, association with PD-L1 expression, and prognostic significance.
    Sun Y; Zhou X; Lucas E; Chen L; Zhang H; Chen H; Zhou F
    J Pathol Clin Res; 2024 Jan; 10(1):e345. PubMed ID: 37798754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characteristics of the immune microenvironment and their clinical significance in non-small cell lung cancer patients with ALK-rearranged mutation.
    Zhang B; Zeng J; Zhang H; Zhu S; Wang H; He J; Yang L; Zhou N; Zu L; Xu X; Song Z; Xu S
    Front Immunol; 2022; 13():974581. PubMed ID: 36159860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.